The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report

BACKGROUND: Systemic treatment of advanced non-small cell lung cancer (NSCLC) has changed dramatically since the introduction of targeted therapies. The analysis of circulating tumor DNA (ctDNA) is a valuable approach to monitor the clonal evolution of tumors during treatment with EGFR-tyrosine kina...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Del Re, Marzia, Rofi, Eleonora, Cappelli, Carla, Puppo, Gianfranco, Crucitta, Stefania, Valeggi, Simona, Chella, Antonio, Danesi, Romano, Petrini, Iacopo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492432/
https://ncbi.nlm.nih.gov/pubmed/31039766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5604-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados